Mammary Cell News

Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.

Serine/Threonine Kinase 33 as a Novel Target of Bufalin in Treatment of Triple-Negative Breast Cancer

September 11, 2025

[Advanced Science] Combining molecular docking, SPR analysis, and Biotin-pulldown analysis, researchers demonstrated that serine/threonine kinase 33 can bind Bufalin, a key active ingredient of the traditional Chinese medicine HuaChansu.

5’-Methylthioadenosine Metabolic Reprogramming Drives H3K79 Monomethylation-Mediated PAK2 Upregulation to Promote Cadmium-Induced Breast Cancer Progression by Impairing Autophagic Flux

September 11, 2025

[Advanced Science] Through the integration of metabolomics, proteomics, and ingenuity pathway analysis, scientists constructed a metabolite–protein regulatory network, which revealed that 5′-methylthioadenosine-mediated metabolic reprogramming plays a core regulatory role in the epigenetic‒autophagy axis involved in cadmium -induced autophagic flux impairment and breast cancer progression.

Oncogenic Role of the SLC7A13-SLC3A1 Cystine Transporter in Human Luminal Breast Cancer and Its Cryo-EM Structure

September 11, 2025

[Protein & Cell] Researchers reported that the gene for SLC7A13, a member of the SLC7A13-SLC3A1 cystine transporter, was amplified and overexpressed in 19.7% and 49.7% of breast cancers, respectively.

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

September 11, 2025

[Personalis, Inc. (BioSpace)] Personalis, Inc. announced its collaboration with a leading breast cancer team from Yale Cancer Center for a single arm Phase II trial of circulating tumor DNA-guided adjuvant therapy with elacestrant in hormone receptor positive HER2 negative breast cancers at risk for late recurrence.

Interferon-Induced Senescent CD8+ T Cells Reduce Anti-PD1 Immunotherapy Efficacy in Early Triple-Negative Breast Cancer

September 11, 2025

[Science Translational Medicine] Scientists used single-cell RNA sequencing, bulk transcriptomics, and pathology assays on samples from 171 patients with early-stage TNBC receiving chemotherapy with or without immunotherapy.

SWI/SNF Functions as a Gatekeeper of Enhancer Chromatin Access to Control Progression of Mesenchymal Triple-Negative Breast Cancer

September 11, 2025

[Cancer Research] By combining functional proteomics and genomics approaches, the authors identified an oncogenic transcriptional network in mesenchymal and invasive TNBC involving the glucocorticoid receptor, GATA6, MYC, and AP-1 transcription factors.

Early Versus Deferred Use of CDK4/6 Inhibitors in Advanced Breast Cancer: Circulating Tumor DNA Analysis of a Randomized Phase III Trial

September 9, 2025

[Nature Medicine] Using prespecified circulating tumor DNA analyses, scientists performed an exploratory study to evaluate whether pretreatment circulating tumor DNA levels in plasma can identify patients that benefit from CDK4/6 inhibitors during their first-line treatment.

Advances of Androgen Receptor in Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Applications

September 9, 2025

[Discover Oncology] The androgen receptor (AR) is highly expressed by TNBC tumor cells and plays a vital role on tumor progression. With more research into AR signaling pathways and functions, AR-targeted therapy is becoming a promising treatment strategy.

Engineering Complexity: Advances in 3D Breast Cancer Models for Precision Oncology

September 9, 2025

[Advanced Healthcare Materials] The authors highlight the current progress in engineering in vitro breast cancer models, comparing their capabilities and discussing innovations aimed at improving their biological accuracy and clinical relevance.

Preclinical Evaluation of Antitumor Activity and Toxicity of TROP2-Specific CAR-T Cells for Treatment of Triple-Negative Breast Cancer

September 9, 2025

[Journal for Immunotherapy of Cancer] Scientists developed a second-generation chimeric antigen receptor that specifically targets trophoblast cell-surface antigen 2 (TROP2) and formally evaluated its antitumor activity and safety profile using in vitro and in vivo models.

Patritumab Deruxtecan in HR+HER2– Advanced Breast Cancer: A Phase II Trial

September 8, 2025

[Nature Medicine] Researchers reported the results of ICARUS-BREAST01, a Phase II study evaluating efficacy, safety and biomarkers of response and resistance to patritumab deruxtecan, in patients with HR⁺HER2>sup− metastatic breast cancer.

Damon Runyon Cancer Research Foundation Awards $4.8 Million to Exceptional Early-Career Scientists

August 29, 2025

[Damon Runyon Cancer Research Foundation] The Damon Runyon Cancer Research Foundation has named 16 new Damon Runyon Fellows. This fellowship encourages young scientists to pursue careers in cancer research by providing them with independent funding to investigate cancer causes, mechanisms, therapies, and prevention.

For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.